Tumor mutational burden and immunotherapy in gliomas.
Trends Cancer
; 7(12): 1054-1058, 2021 12.
Article
en En
| MEDLINE
| ID: mdl-34580037
ABSTRACT
Tumor mutational burden (TMB) is an emerging biomarker for the prediction of immunotherapy success in solid tumors. Gliomas, however, do not demonstrate a correlation between TMB and immunotherapy efficacy. Here, we discuss the potential factors influencing this discordance, focusing on the impact of neoantigen immunogenicity, clonality, expression, and presentation.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Glioma
/
Inmunoterapia
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Trends Cancer
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos